| Product Name | beta Amyloid (1-40) antibody [BAM-10] |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Mouse monoclonal antibody [BAM-10] to beta Amyloid (1-40)The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease. |
| Immunogen | Synthetic peptide conjugated to KLH, corresponding to amino acids 1-40 of beta Amyloid. |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Clone Number | BAM-10 |
| Host Species | Mouse |
| Tested Applications | IHC-FIHC-P |
| IHC-P: Use at an assay dependent dilution. IHC-Fr: Use at an assay dependent dilution. We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Suitable for formalin/paraffin tissues. Optimal dilutions/concentrations should be determined by the end user. | |
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Purification | Protein A |
| Gene Synonyms | AD1, APP, ABETA, CTFgamma, APPI, 351, ABPP, CVAP, beta Amyloid, PN2, 104760, P05067, AAA |
|---|---|
| Target | beta Amyloid (1-40) |
| Tissue Specificity | This antibody reacts with beta amyloid protein. This antibody stains Amyloid plaques within the cortex, and Amyloid deposits in blood vessels. Beta amyloid deposits are also detected in Lewy body dementia, Down?s syndrome, amyloidosis and in Gram-Parkinson dementia complex. The presence to a large number of neuritic plaques (senile) and neurofibrillary tangles in the cerebral cortex is used a pathological marker for a disease state and presents the major criterion for the diagnosis of Alzheimer?s disease at autopsy. |
| Cellular Localization | Type I membrane protein |
| Positive Control | Brain |
|---|---|
| Application Notes | IHC-P: Use at an assay dependent dilution. IHC-Fr: Use at an assay dependent dilution. We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Suitable for formalin/paraffin tissues. Optimal dilutions/concentrations should be determined by the end user. |
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Store at 4ºC short term. For extended storage aliquot and store at -20ºC or below. Avoid freeze-thaw cycles. |
| Storage Buffer | Preservative: Sodium Azide; Constituents: PBS |
